Kura Oncology, Inc.

Kura Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for the treatment of cancer. The company's primary focus is on creating innovative therapies that target specific molecular drivers of cancer, with the aim of providing more effective and personalized treatment options for patients. Kura Oncology is actively engaged in the research and development of small molecule compounds designed to block oncogenic signaling pathways that play a pivotal role in tumor growth and proliferation. The company's research targets hematologic malignancies and solid tumors, with a pipeline that includes product candidates such as tipifarnib, which is under investigation for treating various types of cancer characterized by specific genetic mutations. Notable for its commitment to targeted cancer therapy, Kura Oncology collaborates with leading research institutions and healthcare professionals to advance its clinical trials. Headquartered in San Diego, California, Kura Oncology plays a significant role in the biopharmaceutical industry by contributing to the ongoing evolution of cancer treatment strategies, particularly in the realm of precision medicine. The company’s efforts reflect the increasing trend towards therapies that aim to improve patient outcomes through targeted, genetic-based approaches.